Skip to main content

News All News

Press Contact: Kirsten Mabry | (617) 495-4157

Tag: Blavatnik Biomedical Accelerator

June 9th, 2026

Son’s diabetes diagnosis sent scientist on quest for cure

More than three decades of research by Doug Melton, Catalyst Professor and co-director of the Harvard Stem Cell Institute, led to the launch of Semma Therapeutics and the development of a potential new treatment for Type 1 diabetes that uses stem cells to make healthy insulin-producing cells that can be transplanted into patients. The Blavatnik Biomedical Accelerator supported the research that led to the launch of Semma Therapeutics out of the Melton Lab.

March 9th, 2026

Unlocking hidden pocket on a billion‑dollar drug target

A research team led by Christina Woo, professor of chemistry and chemical biology, in collaboration with a team of scientists at pharmaceutical company GSK and Scripps Research Institute, discovered a hidden binding pocket on the protein cereblon. The discovery of the allosteric cereblon binder could uncover a new area of cereblon biology to explore for cancer drugs.

March 2nd, 2026

'I think I know how to fix this'

Researchers in Andrew Kruse’s lab overcame a key obstacle in using the hormone relaxin as a therapy for heart disease. With support from Harvard’s Blavatnik Biomedical Accelerator, this discovery led to the launch of Tectonic Therapeutic, which is now testing its relaxin-based drug in clinical trials.

Page 2 of 12